Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis

Gracious D.S. Kasheke, Scott P. Holman, George S. Robertson

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

4 Citas (Scopus)

Resumen

Fingolimod, used to treat relapsing-remitting multiple sclerosis (RRMS), reduces motor deficits in mice with established experimental autoimmune encephalomyelitis (EAE). To better characterize the therapeutic effects of fingolimod, kinematic gait analysis was employed to precisely measure movements of a hindleg while EAE mice walked on a treadmill. Relative to the vehicle group, oral dosing with fingolimod, beginning after disease onset (1 mg/kg/day), increased hip heights and knee joint movements, and reduced spinal cord demyelination. These findings suggest that fingolimod preserves gait in RRMS patients by protecting motor circuits in the spinal cord.

Idioma originalEnglish
Número de artículo577926
PublicaciónJournal of Neuroimmunology
Volumen370
DOI
EstadoPublished - sep. 15 2022

Nota bibliográfica

Funding Information:
This work was supported by funding from the Congressionally Directed Medical Research Program (Award number: W81XWH1910579 ).

Publisher Copyright:
© 2022 Elsevier B.V.

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

PubMed: MeSH publication types

  • Journal Article
  • Research Support, U.S. Gov't, Non-P.H.S.

Huella

Profundice en los temas de investigación de 'Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis'. En conjunto forman una huella única.

Citar esto